1. A Randomized, Placebo-Controlled Trial of OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder 
Joseph Biederman, Eric Mick, Craig Surman, Robert Doyle, Paul Hammerness, Theresa Harpold, Stephanie Dunkel, Meghan Dougherty, Megan Aleardi, Thomas Spencer 
Biological Psychiatry 
Volume 59, Issue 9, Pages (May 2006)
DOI: /j.biopsych
Copyright © 2005 Society of Biological Psychiatry Terms and Conditions

2. Figure 1
Flow diagram of subject progress. MPH, methylphenidate; LOCF, last observation carried forward.
Biological Psychiatry  , DOI: ( /j.biopsych )
Copyright © 2005 Society of Biological Psychiatry Terms and Conditions

3. Figure 2
Clinical ratings of attention-deficit/hyperactivity disorder (ADHD) symptoms. P values documenting OROS MPH effect within week calculated from the interaction drug × time indicator variables of the generalized estimating equation model, controlling for baseline AISRS score, age, gender, socioeconomic status, and concomitant antidepressant pharmacotherapy. AISRS, Adult ADHD Investigator System Report Scale; MPH, methylphenidate; LOCF, last observation carried forward.
Biological Psychiatry  , DOI: ( /j.biopsych )
Copyright © 2005 Society of Biological Psychiatry Terms and Conditions

4. Figure 3
Change in DSM-IV symptom clusters at endpoint. ADHD, attention-deficit/hyperactivity disorder; IA, inattentive; HI, hyperactive/impulsive; MPH, methylphenidate.
Biological Psychiatry  , DOI: ( /j.biopsych )
Copyright © 2005 Society of Biological Psychiatry Terms and Conditions

5. Figure 4
Clinical ratings of improvement and response. AISRS, Adult Attention-Deficit/Hyperactivity Disorder Investigator System Report Scale; MPH, methylphenidate.
Biological Psychiatry  , DOI: ( /j.biopsych )
Copyright © 2005 Society of Biological Psychiatry Terms and Conditions